Zanamivir

製品コードS3007 バッチS300702

印刷

化学情報

Chemical Structure Synonyms GG167,GR 121167X Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C12H20N4O7
分子量 332.31 CAS No. 139110-80-8
Solubility (25°C)* 体外 DMSO 66 mg/mL (198.6 mM)
Water 36 mg/mL (108.33 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Zanamivir (GG167,GR 121167X) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.
in vitro

Zanamivir, a novel neuraminidase inhibitor, is effective at decreasing replication of the virus in vitro. [1] Zanamivir results in reduced sensitivity in influenza A/H1N1 variant His274Asn, as well as His274Gly, His274Ser, and His274Gln. [2] Zanamivir blocks influenza neuraminidase and prevents the cleavage of sialic acid residues, thus interfering with progeny virus dispersement within the mucosal secretions and reducing viral infectivity. [3] Zanamivir prevents hemadsorption and fusion of persistently infected cells with uninfected cells. Zanamivir reduces the number (but not the area) of plaques if present only during the adsorption period and reduces plaque area (but not number) if added only after the 90-min adsorption period in plaque assays. Zanamivir also reduces the area of plaques formed by a neuraminidase-deficient variant, confirming that its interference with cell-cell fusion is unrelated to inhibition of neuraminidase activity. Zanamivir has no effect on hemadsorption but does inhibit HA2b-red blood cell fusion, as judged by both lipid mixing and content mixing. [4]
in vivo

Zanamivir reduces lung titers of the virus and decreases morbidity and mortality in a model of lethal challenge in mice. [1]

プロトコル(参考用のみ)

カスタマーフィードバック

, , Emerg Microbes Infec, 2014, 3:e78.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Siglec-G Deficiency Ameliorates Hyper-Inflammation and Immune Collapse in Sepsis via Regulating Src Activation [ Front Immunol, 2019, 10:2575] PubMed: 31781099
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. [ Emerg Microbes Infect, 2014, 3(11):e78] PubMed: 26038501
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. [Zhang XN, et al. Emerg Microbes Infec, 2014, 3, e78]

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。